In the treatment of cardiovascular diseases such as myocardial infarction, heart failure, atherosclerosis, and cardiometabolic disorders, the use of selective CB1R or CB2R agonists or antagonists might have a beneficial effect [2,17,19,26,32,52]. This evidence concerns the gene CNR1 and heart failure.